Aug 10, 2026 09:01AM
Jun 11, 2026 07:30AM
Mar 16, 2026 04:01PM
Dec 11, 2025 04:01PM
Oct 29, 2025 04:24PM
Apr 24, 2025 04:15PM
Mar 26, 2025 06:50AM Rafael Holdings (RFL) Completes Merger with Cyclo Therapeutics (CYTH) Following Shareholder Approvals
Mar 26, 2025 06:50AM
Mar 13, 2025 05:50PM
Dec 11, 2024 07:00AM
Nov 6, 2024 07:14PM
Aug 22, 2024 06:50AM
Aug 22, 2024 06:50AM
Jun 14, 2024 04:01PM Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results
Mar 13, 2024 05:04PM
Nov 15, 2023 08:05AM
Apr 4, 2023 08:09AM
Apr 4, 2023 08:00AM
Apr 4, 2023 08:00AM
Dec 13, 2022 07:00AM
Dec 13, 2022 07:00AM Rafael Holdings Reports First Quarter Fiscal 2023 Financial Results
Nov 15, 2022 04:02PM
Nov 15, 2022 04:01PM
Nov 15, 2022 04:01PM
Jan 21, 2022 07:03AM
Jan 21, 2022 07:00AM
Jan 21, 2022 07:00AM
Jan 18, 2022 08:30AM Rafael Pharmaceuticals Announces Ongoing Successful Enrollment and Opening of Additional Sites for Phase 2 Clinical Trial of CPI-613® (Devimistat) in Combination with Gemcitabine and Cisplatin in Pat
Jan 18, 2022 08:30AM
Jan 6, 2022 08:30AM
Jan 6, 2022 08:30AM
Dec 15, 2021 04:30PM
Dec 15, 2021 04:30PM
Dec 13, 2021 08:00AM
Dec 13, 2021 08:00AM Rafael Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) From Phase 2 Clinical Trial for Refractory Burkitt Lymphoma at the 2021 American Society of Hematology (ASH) Annual Meeting an
Nov 22, 2021 07:00AM
Nov 22, 2021 07:00AM
Nov 11, 2021 09:00AM
Nov 11, 2021 09:00AM
Nov 3, 2021 09:03AM
Nov 3, 2021 09:00AM
Nov 3, 2021 09:00AM European Medicines Agency Grants Orphan Drug Designation to Rafael Pharmaceuticals’ CPI-613® (Devimistat) for Treatment of Patients with Relapsed or Refractory Burkitt's Lymphoma
Oct 28, 2021 08:02AM
Oct 28, 2021 08:00AM
Oct 28, 2021 08:00AM
Oct 28, 2021 07:02AM
Oct 28, 2021 07:00AM
Oct 28, 2021 07:00AM
Oct 18, 2021 05:30PM Rafael Holdings Announces Inducement Grant Under NYSE Rule 303A.08
Oct 18, 2021 05:30PM

1,180,361 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All